序号 |
标题 |
次数 |
作者 |
发布时间 |
62371 |
MC-Val-Cit-PAB-tubulysin5a ,CAS号:2055896-86-9 |
60 |
WYQ |
2024-12-19 |
62372 |
Au_55_C11NH3Cl 金55-C11-NH3Cl |
90 |
h |
2024-12-19 |
62373 |
(S-(CH2)11-(beta-Lactose(SO4Na)7)2 硫-十一烷烃-β-乳糖 |
109 |
h |
2024-12-19 |
62374 |
HS-(CH2)11-O-Disperse Red 1 十一烷烃硫醇化荧光配体 |
152 |
h |
2024-12-19 |
62375 |
HS-(CH2)16-(EG)2 -N(+)(CH3)2-CH2-COO(-) 二聚乙二醇化十六硫醇 |
112 |
h |
2024-12-19 |
62376 |
cas:103750-03-4,5-Maleimido-pentanoic NHS ester,5-马来酰亚胺戊酸NHS |
113 |
kx |
2024-12-19 |
62377 |
4-Nitrophenyl 2-(pyridin-2-yldisulfanyl)propyl carbonate,抗体药物偶联物(ADC) |
113 |
kx |
2024-12-19 |
62378 |
cas:158913-22-5,SPDP-C6-NHS ester,琥珀酰亚胺基6-[3-(2-吡啶基二硫代)丙酰胺基]己酸酯 |
103 |
kx |
2024-12-19 |
62379 |
perfluorophenyl 4-methyl-4-(pyridin-2-yldisulfanyl)pentanoate,抗体药物偶联物(ADC) |
117 |
kx |
2024-12-19 |
62380 |
cas:663598-61-6,2,5-dioxopyrrolidin-1-yl 4-((5-nitropyridin-2-yl)disulfanyl)pentanoate, ADC试剂 |
90 |
kx |
2024-12-19 |
62381 |
perfluorophenyl 4-(pyridin-2-yldisulfanyl)butanoate, ADC试剂 |
74 |
kx |
2024-12-19 |
62382 |
cas:160580-70-1,perfluorophenyl 3-(pyridin-2-yldisulfanyl)propanoate,抗体药物偶联物(ADC) |
112 |
kx |
2024-12-19 |
62383 |
cas:252554-78-2, Fmoc-Ala-Ser(Psi(Me Me)pro)-OH,(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
131 |
kx |
2024-12-19 |
62384 |
MC-Val-Cit-PAB-Indibulin, cas:2055896-95-0 |
79 |
WYQ |
2024-12-19 |
62385 |
cas:1884578-27-1 ,Alloc-Val-Ala-PAB-PNP,N-[(2-丙烯-1-基氧基)羰基]-L-缬氨酸-N-[4-[[(4-硝基苯氧基)羰基]氧基]甲基]苯基]-L-丙氨酸酰胺 |
91 |
kx |
2024-12-19 |
62386 |
mDPR-Val-Cit-PAB-MMAE(CAS:1491152-26-1) |
79 |
WYQ |
2024-12-19 |
62387 |
2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13-tetraoxa-4-azahexadecan-16-oate |
88 |
wyh |
2024-12-19 |
62388 |
MC-Val-Cit-PAB-vinblastine(CAS:2055896-92-7) |
83 |
WYQ |
2024-12-19 |
62389 |
2,5-dioxopyrrolidin-1-yl 1-(bicyclo[6.1.0]non-4-yn-9-yl)-3-oxo-2,7,10,13-tetraoxa-4-azahexadecan-16-oate |
64 |
wyh |
2024-12-19 |
62390 |
MC-Val-Cit-PAB-tubulysin5a(CAS:2055896-86-9) |
86 |
WYQ |
2024-12-19 |
62391 |
N-芴甲氧羰基-四聚乙二醇-VAL-ALA-PAB, Fmoc-PEG4-Val-Ala-PAB |
113 |
kx |
2024-12-19 |
62392 |
MC-Val-Cit-PAB-clindamycin(CAS号:1639793-13-7) |
74 |
WYQ |
2024-12-19 |
62393 |
MC-Val-Cit-PAB-carfilzomib,CAS号:2055896-83-6 |
96 |
WYQ |
2024-12-19 |
62394 |
叔丁酯-四聚乙二醇-VAL-ALA-PAB,Boc-PEG4-Val-Ala-PAB |
69 |
kx |
2024-12-19 |
62395 |
MC-Val-Cit-PAB-Auristatin E,CAS号:2055896-77-8 |
95 |
WYQ |
2024-12-19 |
62396 |
MC-Sq-Cit-PAB-Gefitinib(CAS:1941168-63-3) |
148 |
WYQ |
2024-12-19 |
62397 |
HS-(CH2)m-(EG)n -N(+)(CH3)2-CH2-COO(-) 聚乙二醇化直链烷烃硫醇 |
85 |
h |
2024-12-19 |
62398 |
Mal-PEG4-Val-Ala-PAB,马来酰亚胺-四聚乙二醇-VAL-ALA-PAB |
119 |
kx |
2024-12-19 |
62399 |
MC-GGFG-DX8951(CAS:1600418-29-8) |
252 |
WYQ |
2024-12-19 |
62400 |
(HO)2-PO-S-(CH2)6-EG2-OH 硫-(2-羟基六烷-1-基)硫代磷酸酯 |
117 |
h |
2024-12-19 |
62401 |
Au_55_C11EG4Carboxybetaine 金团簇55-羧基甜菜碱 |
107 |
h |
2024-12-19 |
62402 |
(HO)2-PO-S-(CH2)m-COONHS 硫-(2,5-二氧代 - 吡咯烷-1-基氧基羰基)-1-基硫代磷酸 |
88 |
h |
2024-12-19 |
62403 |
2529982-76-9,Azido-PEG4-Val-Ala-PAB,叠氮-四聚乙二醇-VAL-ALA-PAB |
99 |
kx |
2024-12-19 |
62404 |
Au_12_C11EG6 金团簇12-直链烷烃六聚乙二醇 |
108 |
h |
2024-12-19 |
62405 |
cas:863971-17-9 ,MC-Val-Cit-PAB-MMAF,MC-VAL-CIT-PAB-MMAF游离态 |
74 |
kx |
2024-12-19 |
62406 |
CF3-(CF2)5-C2-O-C11-Si(OMe)3 巯基-直链烷烃连接氟化硫醇和硅烷 |
92 |
h |
2024-12-19 |
62407 |
cas:2353409-69-3 , Mal-PEG8-Val-Cit-PAB-MMAE,马来酰亚胺-八聚乙二醇-VAL-CIT-PAB-MMAE |
66 |
kx |
2024-12-19 |
62408 |
cas:2129164-91-4 , DBCO-PEG4-Val-Cit-PAB-MMAE,二苯并环辛炔-四聚乙二醇-VAL-CIT-PAB-MMAE |
141 |
kx |
2024-12-19 |
62409 |
MAL-di-EG-Val-Cit-PAB-MMAF,由ADC连接桥(MAL-di-EG-Val-Cit-PAB)和有效的微管蛋白聚合阻断剂(MMAF, Monomethyl auristatin F)组成 |
109 |
WYQ |
2024-12-19 |
62410 |
MAL-di-EG-Val-Cit-PAB-MMAE,CAS编号:2746391-62-6 |
111 |
WYQ |
2024-12-19 |
62411 |
cas:644981-35-1 , Val-Cit-PAB-MMAE, ADC试剂 |
66 |
kx |
2024-12-19 |
62412 |
cas:2754384-60-4,DBCO-(PEG)3-VC-PAB-MMAE,抗体药物偶联物(ADC) |
119 |
kx |
2024-12-19 |
62413 |
AcLys-PABC-VC-Aur0101(CAS:1438851-17-2) |
91 |
WYQ |
2024-12-19 |
62414 |
反式环辛烯-MMAE,TCO-MMAE, ADC试剂 |
116 |
kx |
2024-12-19 |
62415 |
Hydrazone-doxorubicin,阿霉素-腙键偶联物 |
150 |
WYQ |
2024-12-19 |